Prior vedolizumab exposure and fibroblast-derived MMP13 are associated with ustekinumab nonresponse in ulcerative colitis - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Association of Previous Vedolizumab Treatment and Fibroblast-Derived MMP13 with Nonresponse to Ustekinumab in Ulcerative Colitis Patients

  • By

  • Yuiko Tsuruta

  • Yoki Furuta

  • Masatoshi Nakashima

  • Cheng Pan

  • Shota Takano

  • Koichi Sakurai

  • Hideki Kitada

  • Kana Omoto

  • Taichi Matsuyama

  • Yoshinari Sakai

  • Suguru Chiyonaga

  • Kotaro Fukubayashi

  • Takashi Shono

  • Masakuni Tateyama

  • Kotaro Waki

  • Munenori Honda

  • Kenshi Matsuno

  • Akira Yamasaki

  • Hideaki Miyamoto

  • Ryosuke Gushima

  • Takehisa Watanabe

  • Katsuya Nagaoka

  • Hideaki Naoe

  • Yoshihiro Komohara

  • Yasuhito Tanaka

  • September 28, 2026

Share

Objective:

To evaluate whether previous vedolizumab treatment influences clinical response to ustekinumab among patients with ulcerative colitis.

Approach:
  • Study Design: A multicenter, retrospective, observational study conducted across 11 institutions in Kumamoto Prefecture, Japan, involving patients with UC who commenced ustekinumab treatment.
  • Data Collection: Data was extracted from medical records, including demographics, disease characteristics, and previous therapy exposure.
  • Outcomes: Primary outcomes included clinical response and remission assessed at 2, 6, and 12 months post-ustekinumab initiation.
Key Findings:
  • Previous exposure to vedolizumab may affect the clinical response to ustekinumab in UC patients, with clinical evaluations showing varying response rates based on prior treatment history.
Limitations:
  • The study was retrospective and observational, which may introduce biases.
  • Advanced therapy-naïve ustekinumab nonresponders were scarce, limiting the analysis.

Original Source(s)

Prior vedolizumab exposure and fibroblast-derived MMP13 are associated with ustekinumab nonresponse in ulcerative colitis

  • by Yuiko Tsuruta, Yoki Furuta, Masatoshi Nakashima, Cheng Pan, Shota Takano, Koichi Sakurai, Hideki Kitada, Kana Omoto, Taichi Matsuyama, Yoshinari Sakai, Suguru Chiyonaga, Kotaro Fukubayashi, Takashi Shono, Masakuni Tateyama, Kotaro Waki, Munenori Honda, Kenshi Matsuno, Akira Yamasaki, Hideaki Miyamoto, Ryosuke Gushima, Takehisa Watanabe, Katsuya Nagaoka, Hideaki Naoe, Yoshihiro Komohara, Yasuhito Tanaka

  • September 28, 2026

Related Content

Median Arcuate Ligament Syndrome Masked by Cannabis Hyperemesis Syndrome: A Case Report

  • September 15, 2026

Long-term outcomes in recurrent diverticulitis: a systematic review of treatment strategies and recurrence rates

Racial disparities in the rate of same-admission cholecystectomy following biliary pancreatitis